-
1.
公开(公告)号:US20160184356A1
公开(公告)日:2016-06-30
申请号:US14776929
申请日:2014-03-14
申请人: Ke Jian Jim LIU , Laurie HUDSON , Karen COOPER , Xixi ZHOU , STC.UNM
发明人: Ke Jian Jim Liu , Laurie Hudson , Karen Cooper , Xixi Zhou
CPC分类号: A61K33/36 , A61K31/166 , A61K31/407 , A61K31/4184 , A61K31/4188 , A61K31/454 , A61K31/502 , A61K31/5025 , A61K31/55 , A61K31/555 , A61K31/7068 , A61K41/0038 , A61K45/06 , A61N2005/1098 , A61K2300/00
摘要: In one embodiment, the invention provides a method of treating a subject who suffers from a cancer (particularly a chemotherapeutic or radiotherapeutic-resistant cancer) or from an inflammatory disorder, the method comprising co-administering to the subject a pharmaceutically-effective amount of: (a) one or more elements or compounds selected from the group consisting of arsenic, an arsenite and arsenic trioxide (ATO); and optionally (b) at least one anticancer agent (preferably a DNA damaging agent); and/or (c) at least one or more Poly(ADP-ribose) polymerase (PARP) inhibitors other than arsenic, an arsenite and arsenic trioxide (ATO). In preferred embodiments, the arsenic for the treatment of cancer, arsenite and ATO serve as radio sensitizers for concomitant radiotherapy as well as PARP inhibitors. Methods for treating inflammatory disease are also disclosed. Related pharmaceutical formulations are also provided.
摘要翻译: 在一个实施方案中,本发明提供了治疗患有癌症(特别是化学治疗或放射治疗耐药性癌症)或炎症性疾病的受试者的方法,所述方法包括向受试者共同施用药物有效量的: (a)选自砷,亚砷酸钠和三氧化二砷(ATO)中的一种或多种元素或化合物; 和(b)至少一种抗癌剂(优选DNA损伤剂); 和/或(c)至少一种或多种除砷以外的聚(ADP-核糖)聚合酶(PARP)抑制剂,亚砷酸钠和三氧化二砷(ATO))。 在优选实施方案中,用于治疗癌症,亚砷酸盐和ATO的砷用作伴随放射治疗的放射敏化剂以及PARP抑制剂。 还公开了治疗炎性疾病的方法。 还提供了相关的药物制剂。